Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 0.47 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1318008 | 0.94 | MMP13 (0.43) | MMP13PYGLNPC1RAB9AF2 | |
| SCHEMBL1300026 | 0.84 | PYGL (0.44) | MMP13PYGLNPC1RAB9A | |
| SCHEMBL1319100 | 0.84 | MMP13 (0.47) | MMP13 | |
| SCHEMBL1319743 | 0.81 | MMP13 (0.54) | MMP13 | |
| SCHEMBL1300152 | 0.79 | PYGL (0.48) | PYGLNPC1RAB9A | |
| SCHEMBL1300636 | 0.79 | RAB9A (0.46) | PYGLNPC1RAB9A | |
| SCHEMBL1317254 | 0.78 | MCHR1 (0.44) | MMP13PYGLNPC1RAB9A | |
| SCHEMBL1317535 | 0.78 | MAPT (0.54) | NPC1RAB9A | |
| SCHEMBL1300144 | 0.78 | PYGL (0.47) | PYGLMAP4K4 | |
| SCHEMBL1299819 | 0.77 | PYGL (0.44) | PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275625-A1 | Heteroaryl Diamide Compounds Useful as MMP-13 Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| EP-2346831-A2 | HETEROARYL DIAMIDE COMPOUNDS USEFUL AS MMP-13 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275625-A1 | Heteroaryl Diamide Compounds Useful as MMP-13 Inhibitors | MMP13, MMP3, MMP11 | MMP13 1/4885PYGL 2049/4885NPC1 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.